Use of a new proximity assay (NanoBRET) to investigate the ligand-binding characteristics of three fluorescent ligands to the human <i>β</i><sub>1</sub>-adrenoceptor expressed in HEK-293 cells.

Pharmacol Res Perspect · 2016 · PMC4988514 · PMID 27588207

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantP < 0.001actually significant

In the case of CGP20712A and CGP 12177, the differences were highly significant ( P < 0.001; one‐way ANOVA; Fig. 10 A).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Use of a new proximity assay (NanoBRET) to investigate the ligand-binding characteristics of three fluorescent ligands to the human &lt;i&gt;β&lt;/i&gt;&lt;sub&gt;1&lt;/sub&gt;-adrenoceptor expressed in HEK-293 cells.

The sentences

Use of a new proximity assay (NanoBRET) to investigate the ligand-binding characteristics of three fluorescent ligands to the human <i>β</i><sub>1</sub>-adrenoceptor expressed in HEK-293 cells.